• 1. Liptak JM, Dernell WS, Erhart N, et al. Canine appendicular osteosarcoma: diagnosis and palliative treatment. Compend Contin Educ Pract Vet 2004; 26:172182.

    • Search Google Scholar
    • Export Citation
  • 2. Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991; 5:205210.

    • Search Google Scholar
    • Export Citation
  • 3. Mauldin GN, Matus RE, Withrow SJ, et al. Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988; 2:177180.

    • Search Google Scholar
    • Export Citation
  • 4. Spodnick GJ, Berg J, Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 1992; 200:995999.

    • Search Google Scholar
    • Export Citation
  • 5. Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979–1990). J Am Vet Med Assoc 1992; 200:531533.

    • Search Google Scholar
    • Export Citation
  • 6. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996; 10:7681.

    • Search Google Scholar
    • Export Citation
  • 7. Phillips B, Powers BE, Dernell WS, et al. Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. J Am Anim Hosp Assoc 2009; 45:3338.

    • Search Google Scholar
    • Export Citation
  • 8. Vail DM, Kurzman ID, Glawe PC, et al. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother Pharmacol 2002; 50:131136.

    • Search Google Scholar
    • Export Citation
  • 9. Hillers KR, Dernell WS, Lafferty MH, et al. Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003). J Am Vet Med Assoc 2005; 226:13641367.

    • Search Google Scholar
    • Export Citation
  • 10. Garzotto CK, Berg J, Hoffmann WE, et al. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 2000; 14:587592.

    • Search Google Scholar
    • Export Citation
  • 11. Kirpensteijn J, Kik M, Rutteman GR, et al. Prognostic significance of a new histologic grading system for canine osteosarcoma. Vet Pathol 2002; 39:240246.

    • Search Google Scholar
    • Export Citation
  • 12. Liptak JM, Dernell WS, Ehrhart N, et al. Cortical allograft and endoprosthesis for limb-sparing surgery in dogs with distal radial osteosarcoma: a prospective clinical comparison of two different limb-sparing techniques. Vet Surg 2006; 35:518533.

    • Search Google Scholar
    • Export Citation
  • 13. Lascelles BD, Dernell WS, Correa MT, et al. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol 2005; 12:10731083.

    • Search Google Scholar
    • Export Citation
  • 14. Kuntz CA, Asselin TL, Dernell WS, et al. Limb salvage surgery for osteosarcoma of the proximal humerus: outcome in 17 dogs. Vet Surg 1998; 27:417422.

    • Search Google Scholar
    • Export Citation
  • 15. Shapiro W, Fossum TW, Kitchell BE, et al. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988; 192:507511.

    • Search Google Scholar
    • Export Citation
  • 16. Kraegel SA, Madewell BR, Simonson E, et al. Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986–1989). J Am Vet Med Assoc 1991; 199:10571059.

    • Search Google Scholar
    • Export Citation
  • 17. Bailey D, Erb H, Williams L, et al. Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. J Vet Intern Med 2003; 17:199205.

    • Search Google Scholar
    • Export Citation
  • 18. Kent MS, Strom A, London CA, et al. Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. J Vet Intern Med 2004; 18:540544.

    • Search Google Scholar
    • Export Citation
  • 19. Bacon NJ, Ehrhart NP, Dernell WS, et al. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999–2006). J Am Vet Med Assoc 2008; 232:15041510.

    • Search Google Scholar
    • Export Citation
  • 20. Berg J, Weinstein MJ, Springfield DS, et al. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995; 206:15551560.

    • Search Google Scholar
    • Export Citation
  • 21. Chun R, Garrett LD, Henry C, et al. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. J Am Anim Hosp Assoc 2005; 41:382387.

    • Search Google Scholar
    • Export Citation
  • 22. Moore AS, Dernell WS, Ogilvie GK, et al. Doxorubicin and BAY 12–9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study. J Vet Intern Med 2007; 21:783790.

    • Search Google Scholar
    • Export Citation
  • 23. Page RL, McEntee MC, George SL, et al. Pharmacokinetic and phase I evaluation of carboplatin in dogs. J Vet Intern Med 1993; 7:235240.

    • Search Google Scholar
    • Export Citation
  • 24. Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997; 11:279283.

    • Search Google Scholar
    • Export Citation
  • 25. Ogilvie GK, Krawiec DR, Gelberg HB, et al. Evaluation of a short-term saline diuresis protocol for the administration of cisplatin. Am J Vet Res 1988; 49:10761078.

    • Search Google Scholar
    • Export Citation
  • 26. Ogilvie GK, Straw RC, Powers BE, et al. Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987–1989). J Am Vet Med Assoc 1991; 199:613616.

    • Search Google Scholar
    • Export Citation
  • 27. Withrow SJ, Straw RC, Brekke JH, et al. Slow release adjuvant cisplatin for treatment of metastatic canine osteosarcoma. Eur J Exp Musculoskeletal Res 1995; 4:105110.

    • Search Google Scholar
    • Export Citation
  • 28. Mehl ML, Seguin B, Dernell WS, et al. Survival analysis of one versus two treatments of local delivery cisplatin in a biodegradable polymer for canine osteosarcoma. Vet Comp Oncol 2005; 3:8186.

    • Search Google Scholar
    • Export Citation
  • 29. Straw RC, Withrow SJ, Douple EB, et al. Effects of cis-diamminedichloroplatinum II released from D,L-polylactic acid implanted adjacent to cortical allografts in dogs. J Orthop Res 1994; 12:871877.

    • Search Google Scholar
    • Export Citation
  • 30. Fox LE. Carboplatin. J Am Anim Hosp Assoc 2000; 36:1314.

  • 31. Spugnini EP, Crispi S, Scarabello A, et al. Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations. J Exp Clin Cancer Res 2008; 27:6.

    • Search Google Scholar
    • Export Citation
  • 32. Charney SC, Bergman PJ, McKnight JA, et al. Evaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions: a retrospective analysis of 12 cases (1997–2002). Vet Comp Oncol 2005; 3:171181.

    • Search Google Scholar
    • Export Citation
  • 33. de Vos JP, Burm AG, Focker BP. Results from the treatment of advanced stage squamous cell carcinoma of the nasal planum in cats, using a combination of intralesional carboplatin and superficial radiotherapy: a pilot study. Vet Comp Oncol 2004; 2:7581.

    • Search Google Scholar
    • Export Citation
  • 34. Theon AP, VanVechten MK, Madewell BR. Intratumoral administration of carboplatin for treatment of squamous cell carcinomas of the nasal plane in cats. Am J Vet Res 1996; 57:205210.

    • Search Google Scholar
    • Export Citation
  • 35. Fossum TW. Small animal surgery. 2nd ed. St Louis: Mosby, 2002.

  • 36. Royal Childrens Hospital Melbourne. Clinical guidelines (hospital), cytotoxic drugs—the management of. Available at: www.rch.org.au/rchcpg/index.cfm?doc_id=8948. Accessed Feb 28, 2011.

  • 37. Vail DM. Veterinary Co-operative Oncology Group. Vet Comp Oncol 2004; 2:194213.

  • 38. Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005; 3:7380.

    • Search Google Scholar
    • Export Citation
  • 39. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989–2000). J Am Vet Med Assoc 2001; 218:14441448.

    • Search Google Scholar
    • Export Citation
  • 40. Slatter D. Textbook of small animal surgery. 3rd ed. Philadelphia: Saunders, 2003.

  • 41. Brown DC, Conzemius MG, Shofer F, et al. Epidemiologic evaluation of postoperative wound infections in dogs and cats. J Am Vet Med Assoc 1997; 210:13021306.

    • Search Google Scholar
    • Export Citation
  • 42. Vasseur PB, Levy J, Dowd E, et al. Surgical wound infection rates in dogs and cats. Data from a teaching hospital. Vet Surg 1988; 17:6064.

    • Search Google Scholar
    • Export Citation
  • 43. Withrow SJ, Liptak JM, Straw RC, et al. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. Ann Surg Oncol 2004; 11:705713.

    • Search Google Scholar
    • Export Citation
  • 44. Straw RC, Withrow SJ. Limb-sparing surgery versus amputation for dogs with bone tumors. Vet Clin North Am Small Anim Pract 1996; 26:135143.

    • Search Google Scholar
    • Export Citation
  • 45. Dernell WS, Withrow SJ, Straw RC, et al. Adjuvant chemotherapy using cisplatin by subcutaneous administration. In Vivo 1997; 11:345350.

    • Search Google Scholar
    • Export Citation
  • 46. Bacci G, Mercuri M, Briccoli A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 1997; 79:245254.

    • Search Google Scholar
    • Export Citation
  • 47. Picci P, Vanel D, Briccoli A, et al. Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation. Ann Oncol 2001; 12:16011604.

    • Search Google Scholar
    • Export Citation
  • 48. Vanel D, Henry-Amar M, Lumbroso J, et al. Pulmonary evaluation of patients with osteosarcoma: roles of standard radiography, tomography, CT, scintigraphy, and tomoscintigraphy. AJR Am J Roentgenol 1984; 143:519523.

    • Search Google Scholar
    • Export Citation
  • 49. Chalmers N, Best JJ. The significance of pulmonary nodules detected by CT but not by chest radiography in tumour staging. Clin Radiol 1991; 44:410412.

    • Search Google Scholar
    • Export Citation
  • 50. Morello E, Buracco P, Martano M, et al. Bone allografts and adjuvant cisplatin for the treatment of canine appendicular osteosarcoma in 18 dogs. J Small Anim Pract 2001; 42:6166.

    • Search Google Scholar
    • Export Citation

Advertisement

Evaluation of a single subcutaneous infusion of carboplatin as adjuvant chemotherapy for dogs with osteosarcoma: 17 cases (2006–2010)

View More View Less
  • 1 Southpaws Specialty Surgery for Animals, 3 Roper St, Moorabbin, VIC 3189, Australia.
  • | 2 Southpaws Specialty Surgery for Animals, 3 Roper St, Moorabbin, VIC 3189, Australia.
  • | 3 Southpaws Specialty Surgery for Animals, 3 Roper St, Moorabbin, VIC 3189, Australia.
  • | 4 Southpaws Specialty Surgery for Animals, 3 Roper St, Moorabbin, VIC 3189, Australia.
  • | 5 Southpaws Specialty Surgery for Animals, 3 Roper St, Moorabbin, VIC 3189, Australia.

Abstract

Objective—To evaluate adverse effects and survival times in dogs with osteosarcoma that received a single SC infusion of carboplatin as adjunctive chemotherapeutic treatment following limb amputation or limb-sparing surgery.

Design—Retrospective case series.

Animals—17 client-owned dogs with spontaneously occurring osteosarcoma.

Procedures—Medical records of dogs that underwent limb amputation or limb-sparing surgery followed by a single continuous SC infusion of carboplatin (total dose, 300 mg/m2 infused over 3, 5, or 7 days) were evaluated. Signalment, tumor location, type of surgery (amputation or limb-sparing), duration of carboplatin infusion, results of hematologic and serum biochemical analyses, and adverse effects were recorded. Kaplan-Meier survival analysis was performed.

Results—Median survival time for all dogs was 365 days. Nine dogs had adverse bone marrow–related (hematologic) effects, 1 had adverse gastrointestinal effects, and 7 had infections at the surgical site. No significant differences were detected in survival times of dogs grouped according to tumor location, type of surgery, duration of carboplatin infusion, or development of postoperative infection.

Conclusions and Clinical Relevance—Median survival time and adverse effects in dogs with osteosarcoma that received a single SC infusion of carboplatin over a 3-, 5-, or 7-day period as adjunctive treatment following limb amputation or limb-sparing surgery were comparable to those of previously reported chemotherapy protocols requiring IV drug administration over several weeks. Further investigation is needed to evaluate the efficacy of this protocol as adjunctive treatment for osteosarcoma and other tumors in dogs.

Abstract

Objective—To evaluate adverse effects and survival times in dogs with osteosarcoma that received a single SC infusion of carboplatin as adjunctive chemotherapeutic treatment following limb amputation or limb-sparing surgery.

Design—Retrospective case series.

Animals—17 client-owned dogs with spontaneously occurring osteosarcoma.

Procedures—Medical records of dogs that underwent limb amputation or limb-sparing surgery followed by a single continuous SC infusion of carboplatin (total dose, 300 mg/m2 infused over 3, 5, or 7 days) were evaluated. Signalment, tumor location, type of surgery (amputation or limb-sparing), duration of carboplatin infusion, results of hematologic and serum biochemical analyses, and adverse effects were recorded. Kaplan-Meier survival analysis was performed.

Results—Median survival time for all dogs was 365 days. Nine dogs had adverse bone marrow–related (hematologic) effects, 1 had adverse gastrointestinal effects, and 7 had infections at the surgical site. No significant differences were detected in survival times of dogs grouped according to tumor location, type of surgery, duration of carboplatin infusion, or development of postoperative infection.

Conclusions and Clinical Relevance—Median survival time and adverse effects in dogs with osteosarcoma that received a single SC infusion of carboplatin over a 3-, 5-, or 7-day period as adjunctive treatment following limb amputation or limb-sparing surgery were comparable to those of previously reported chemotherapy protocols requiring IV drug administration over several weeks. Further investigation is needed to evaluate the efficacy of this protocol as adjunctive treatment for osteosarcoma and other tumors in dogs.

Contributor Notes

Address correspondence to Dr. Simcock (Jsimcock@me.com).